The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
scFv Antibody: Principles and Clinical Application
Open accessAbstract
To date, generation of single-chain fragment variable (scFv) has become an established technique used to produce a completely functional antigen-binding fragment in bacterial systems. The advances in antibody engineering have now facilitated a more efficient and generally applicable method to produce Fv fragments. Basically, scFv antibodies produced from phage display can be genetically fused to the marker proteins, such as fluorescent proteins or alkaline phosphatase. These bifunctional proteins having both antigen-binding capacity and marker activity can be obtained from transformed bacteria and used for one-step immunodetection of biological agents. Alternatively, antibody fragments could also be applied in the construction of immunotoxins, therapeutic gene delivery, and anticancer intrabodies for therapeutic purposes. This paper provides an overview of the current studies on the principle, generation, and application of scFv. The potential of scFv in breast cancer research is also discussed in this paper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colowick, S. P., Joshi, M. D., Jagannathan, & KAPLAN, N. O. (1966) · Cited by 26,137
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension
Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K., & Pease, L. R. (1989) · Gene · doi:10.1016/0378-1119(89)90359-4 · Cited by 3,017
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,603
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,593
Making antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
Recombinant protein expression in Escherichia coli
Baneyx, F. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00003-8 · Cited by 1,481
Cited by
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Nanoparticle-Based Immunochemical Biosensors and Assays: Recent Advances and Challenges
Farka, Z., Juřík, T., Kovář, D., Trnková, L., & Skládal, P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00037 · Cited by 694
Biosensors for Whole-Cell Bacterial Detection
Ahmed, A., Rushworth, J. V., Hirst, N. A., & Millner, P. A. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00120-13 · Cited by 666
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Liu, J. K. H. (2014) · Annals of Medicine & Surgery · doi:10.1016/j.amsu.2014.09.001 · Cited by 515
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Antibodies and antibody-derived analytical biosensors
Sharma, S., Byrne, H., & O'Kennedy, R. J. (2016) · Essays in Biochemistry · doi:10.1042/ebc20150002 · Cited by 396
Tau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359
“Although relatively underutilized in the neurodegeneration field, scFvs have been extensively used for the diagnosis and treatment of different cancers due to their small size (25 kDa compared to 150 kDa for a full-length antibody) and increased tissue penetration while retaining specificity and high affinity for the…”
BackgroundSynthesis, Assembly, and Applications of Hybrid Nanostructures for Biosensing
Zhang, S., Geryak, R., Geldmeier, J., Kim, S., & Tsukruk, V. V. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00088 · Cited by 340
Design and Production of Bispecific Antibodies
Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., & Betenbaugh, M. J. (2019) · Antibodies · doi:10.3390/antib8030043 · Cited by 279
Microbials for the production of monoclonal antibodies and antibody fragments
Spadiut, O., Capone, S., Krainer, F., Glieder, A., & Herwig, C. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.10.002 · Cited by 258
Tiwari, P., Yadav, K., Shukla, R. P., Gautam, S., Marwaha, D., Sharma, M., & Mishra, P. R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.016 · Cited by 88
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy
Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57
A collagen‐binding EGFR single‐chain Fv antibody fragment for the targeted cancer therapy
Liang, H., Li, X., Chen, B., Wang, B., Zhao, Y., Zhuang, Y., Shen, H., Zhang, Z., & Dai, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.029 · Cited by 54
Sina, M., Farajzadeh, D., & Dastmalchi, S. (2015) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2015.062 · Cited by 26
Lampe, H., Tam, L., & Hansen, A. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399802 · Cited by 21
Petrus, M. L. C., Kiefer, L. A., Puri, P., Heemskerk, E., Seaman, M. S., Barouch, D. H., Arias, S., van Wezel, G. P., & Havenga, M. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10145-1 · Cited by 21
Construction and periplasmic expression of the Anti-EGFRvIII ScFv antibody gene in Escherichia coli
DEWI, K. S. (2016) · Scientia Pharmaceutica · doi:10.3797/scipharm.isp.2015.06 · Cited by 18
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines
del Moral-Sánchez, I., Wee, E. G., Xian, Y., Lee, W.-H., Allen, J. D., Torrents de la Peña, A., Fróes Rocha, R., Ferguson, J., León, A. N., Koekkoek, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00862-8 · Cited by 14
Metadata
- Authors
- Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B. M., & Hamid, M.
- Venue
- Clinical and Developmental Immunology
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-15
- ISSN
- 1740-2522 (ISSN-L)
- 1740-2530
- OpenAlex
- W2014158928
- Cited by
- 760
- References
- 111
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.